The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance
Open accessAbstract
As the standard treatments for cancer, chemotherapy and radiotherapy have been widely applied to clinical practice worldwide. However, the resistance to cancer therapies is a major challenge in clinics and scientific research, resulting in tumor recurrence and metastasis. The mechanisms of therapy resistance are complicated and result from multiple factors. Among them, non-coding RNAs (ncRNAs), along with their modifiers, have been investigated to play key roles in regulating tumor development and mediating therapy resistance within various cancers, such as hepatocellular carcinoma, breast cancer, lung cancer, gastric cancer, etc. In this review, we attempt to elucidate the mechanisms underlying ncRNA/modifier-modulated resistance to chemotherapy and radiotherapy, providing some therapeutic potential points for future cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Natural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Long Noncoding RNAs: Cellular Address Codes in Development and Disease
Batista, P. J., & Chang, H. Y. (2013) · Cell · doi:10.1016/j.cell.2013.02.012 · Cited by 2,531
Extensive translation of circular RNAs driven by N6-methyladenosine
Yang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., Jin, Y., Yang, Y., Chen, L.-L., Wang, Y., et al. (2017) · Cell Research · doi:10.1038/cr.2017.31 · Cited by 1,855
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784
Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00121-7 · Cited by 413 · cited 6×
“Taken together, it is plausible that various lncRNAs contribute to different mechanisms of drug resistance in HCC via modulating downstream pathways, like inhibiting phosphorylation, involving in metabolism, inducing MDR expression, and so on, which provides some new ideas for improvement of therapies.”
BackgroundInfluentialSelf-citationSmall nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
Liao, J., Yu, L., Mei, Y., Guarnera, M., Shen, J., Li, R., Liu, Z., & Jiang, F. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-198 · Cited by 293
Self-citation
Cited by
miRNA-based biomarkers, therapies, and resistance in Cancer
He, B., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., Xie, H., Peng, X., Yin, W., Tao, Y., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.47203 · Cited by 625
Self-citationPI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Small nucleolar RNA and its potential role in breast cancer – A comprehensive review
Dsouza, V. L., Adiga, D., Sriharikrishnaa, S., Suresh, P. S., Chatterjee, A., & Kabekkodu, S. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188501 · Cited by 48
MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells
Liang, H., Xu, Y., Zhang, Q., Yang, Y., Mou, Y., Gao, Y., Chen, R., Chen, C., & Dai, P. (2019) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2019.1569530 · Cited by 43
Metadata
- Authors
- Zhang, X., Xie, K., Zhou, H., Wu, Y., Li, C., Liu, Y., Liu, Z., Xu, Q., Liu, S., Xiao, D., & Tao, Y.
- Venue
- Molecular Cancer
- Published
- 2020-03-02
- Volume
- 19
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W3009337396
- Cited by
- 237
- References
- 8
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. https://app.cochat.ai/papers/10.1186/s12943-020-01171-z
- The paper
- Zhang, X., Xie, K., Zhou, H., Wu, Y., Li, C., Liu, Y., Liu, Z., Xu, Q., Liu, S., Xiao, D., & Tao, Y. (2020). Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Molecular Cancer. https://doi.org/10.1186/s12943-020-01171-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.